- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES – OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Plus Therapeutics, Inc. for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on March 5, 2024, (the “Report”), Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that:
|
| By: |
| /s/ Marc H. Hedrick, MD |
Dated: March 5, 2024 |
|
|
| Marc H. Hedrick, MD |
|
|
|
| President & Chief Executive Officer |
|
|
|
|
|
|
| By: |
| /s/ Andrew Sims |
Dated: March 5, 2024 |
|
|
| Andrew Sims |
|
|
|
| Chief Financial Officer |